Zura Bio Ltd
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
ZURA$1.41+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Three Months Ended March 31 | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(24,223) | $(17,442) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Share-based compensation expense | 5,008 | 3,644 |
| Depreciation and amortization | 16 | 9 |
| Foreign exchange transaction loss | 2 | 24 |
| Loss on disposal of property and equipment | 3 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,493 | 1,123 |
| Accounts payable and accrued expenses | (1,222) | 1,579 |
| Net cash used in operating activities | (18,923) | (11,063) |
| Cash flows from investing activities | ||
| Purchase of property and equipment | (13) | (49) |
| Net cash used in investing activities | (13) | (49) |
| Cash flows from financing activities | ||
| Proceeds from issuance of Class A Ordinary Shares in connection with February 2026 Equity Offering, net of $8.0 million of underwriters’ fees and discounts | 123,875 | — |
| Proceeds from issuance of Pre-Funded Warrants in connection with February 2026 Equity Offering, net of $0.7 million of underwriters’ fees and discounts | 11,248 | — |
| Proceeds from issuance of Class A Ordinary Shares in connection with a sale under the ATM, net of $0.2 million of commissions | — | 5,093 |
| Proceeds from exercise of stock options | — | 90 |
| Net cash provided by financing activities | 135,123 | 5,183 |
| Net increase (decrease) in cash and cash equivalents | 116,187 | (5,929) |
| Cash and cash equivalents, beginning of period | 109,407 | 176,498 |
| Cash and cash equivalents, ending of period | $225,594 | $170,569 |
| Supplemental Disclosure | ||
| Cash paid for taxes | $— | $— |
| Cash paid for interest | $— | $— |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities | ||
| Purchase of property and equipment included in accounts payable and accrued expenses | $5 | $— |
| Transaction costs for February 2026 Equity Offering included in accounts payable and accrued expenses | $550 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.